Kinoxis Therapeutics is an Australian clinical-stage biotechnology company developing first-in-class, brain-penetrant small-molecule inhibitors of ALOX15, an enzyme implicated in neuroinflammation and neurodegeneration. Founded in 2017 as a University of Sydney spinout and based in Melbourne, the company is advancing KNX100, a short-acting ALOX15 inhibitor in the CARES-X Phase 2 trial for agitation associated with dementia, alongside next-generation long-acting candidates such as KNX101 targeting chronic agitation and pain. It is also evaluating alcohol use disorder as an indication expansion opportunity and pursues partnerships across neuropsychiatry and pain.
1
Round
1
Industry
5
Tags
Sep 22, 2026
Latest raise
Funding activity · 1 round
Sep 22, 2026
AUD 6.8M
Series B
Led by Main Sequence
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
